Intratumor heterogeneity in BRCA1-mutated breast cancer metastasis
BRCA1 突变乳腺癌转移的瘤内异质性
基本信息
- 批准号:10680318
- 负责人:
- 金额:$ 4.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-09 至 2025-05-08
- 项目状态:未结题
- 来源:
- 关键词:AnimalsAntibodiesBRCA1 MutationBRCA1 geneBioinformaticsBiological AssayBrainBreast cancer metastasisCancer BiologyCause of DeathCell Differentiation processCellsCessation of lifeChromatinClonal EvolutionComplexComputer AnalysisCustomDNADNA RepairDNA copy numberDNA sequencingDataDevelopmentDiseaseDisseminated Malignant NeoplasmDuct (organ) structureEducational process of instructingEpigenetic ProcessEpithelial CellsEvolutionFacultyGene ExpressionGene Expression ProfileGeneticGenetic TranscriptionGenomic InstabilityGenomicsGenotypeGoalsHarvestHeterogeneityHuman ResourcesImpairmentInjectionsInvestigationLaboratoriesLaboratory AnimalsLearningLiverLocalized Malignant NeoplasmLungMalignant - descriptorMalignant NeoplasmsMammary NeoplasmsMentorsMetastatic breast cancerMethodologyMilkMissionModelingMouse StrainsMultiomic DataMusMutant Strains MiceMutateMutationMutation AnalysisMyoepithelial cellNeoplasm MetastasisOrganPatientsPatternPhenotypePilot ProjectsPopulationPositioning AttributePostdoctoral FellowPrimary NeoplasmPropertyRNAResistanceResolutionStudentsSurveysSystems BiologyTP53 geneTechniquesTechnologyTestingTrainingTreesVariantWomanWorkXCL1 geneadvanced breast cancerbioinformatics toolcancer cellcancer genomicscell typedata integrationdesignepigenomicsexomeexome sequencingexperimental studygenomic toolsimprovedinnovationinsightmalignant breast neoplasmmammary epitheliummetastatic processmolecular markermolecular oncologymolecular pathologymouse modelmultiple omicsmutantneoplastic cellpersonalized medicinepreventprogenitorstem cellssymposiumtranscriptomicstumortumor heterogeneityundergraduate student
项目摘要
Abstract
Metastasis continues to cause the vast majority of breast cancer related deaths because the metastatic
process is poorly understood and therapies for effectively inhibiting it do not exist. Women with BRCA1
mutations develop the most aggressive, and highly metastatic basal-like breast cancer at a high rate. Despite
resembling basal epithelial cells, recent studies have identified the luminal progenitor as the cell type which
undergoes malignant transformation in basal-like breast cancer. Preliminary sequencing data included in this
proposal, from same-cell gene expression and chromatin accessibility epigenetics assay in a mouse model of
basal-like breast cancer, reveal the presence of several differentiation states of luminal progenitor cells within
the tumor. Additionally, several tumor cell states appear to have unique DNA copy-number mutational
signatures. These observations prompt the questions of whether a particular differentiation state is involved in
metastasis and if mutations drive the differentiation and metastasis trajectory.
To investigate the metastatic potentials of the cellular differentiation states and mutational cell subpopulations
in the tumors, the proposed study will consist of the following methodological steps: 1) harvesting
spontaneously generated Brca1&p53-mutant mouse tumors, 2) injection of tumor cells into mice to generate
metastasis replicates, 3) isolation of metastatic cells using mouse strain-specific antibodies, 4) splitting of
metastatic cells and original mammary tumor cells for parallel single cell profiling with a) gene expression and
chromatin accessibility assay and b) custom-built high-resolution mutation panel, 5) data integration to
incorporate the contribution of mutations, epigenetic chromatin states, and gene expression, 6) computational
comparison of metastatic cells to original tumor cells. This study is expected to reveal the molecular markers
which define metastatic cells in Brca1&p53-mutant tumors to inspire metastasis inhibiting therapy.
This study will be carried out by a student with substantial training in molecular pathology and systems biology
who wishes to further her cancer genomics and bioinformatics training. Laboratory animal personnel will assist
with animal work, the bioinformatics director will guide the computational analysis and statistical tests, and the
faculty advisor/sponsor will oversee experiments and interpretations of results. The student will work closely
with the sponsor and the bioinformatics collaborator to learn the proper use of cutting edge genomics and
bioinformatics tools to advance the breast cancer metastasis field. Additionally, the student will be given
professional development opportunities such as attending conferences, mentoring undergraduates, and
teaching a summer course to prepare her for a post-doctoral position in a cancer-related field.
摘要
转移继续导致绝大多数乳腺癌相关死亡,因为转移性乳腺癌是乳腺癌的主要原因。
该过程知之甚少,并且不存在有效抑制该过程的疗法。BRCA 1女性
突变以高比率发展最具侵袭性和高转移性的基底样乳腺癌。尽管
与基底上皮细胞相似,最近的研究已经确定腔祖细胞是
在基底样乳腺癌中发生恶性转化。初步测序数据包括在此
建议,从同一细胞的基因表达和染色质可及性表观遗传学试验在小鼠模型,
基底样乳腺癌,揭示了腔内祖细胞的几种分化状态的存在,
肿瘤此外,几种肿瘤细胞状态似乎具有独特的DNA拷贝数突变,
签名.这些观察结果提示了一个问题,即一个特定的分化状态是否参与了
转移,并且如果突变驱动分化和转移轨迹。
探讨细胞分化状态和突变细胞亚群的转移潜能
在肿瘤中,拟议的研究将包括以下方法步骤:1)收获
自发产生的Brca1&p53突变小鼠肿瘤,2)将肿瘤细胞注射到小鼠中以产生
转移重复,3)使用小鼠品系特异性抗体分离转移细胞,4)分离转移细胞,
转移细胞和原始乳腺肿瘤细胞进行平行单细胞分析,a)基因表达和
染色质可及性测定和B)定制的高分辨率突变面板,5)数据整合,
结合突变、表观遗传染色质状态和基因表达的贡献,6)计算
转移细胞与原始肿瘤细胞的比较。这项研究有望揭示
其定义了Brca 1和p53突变肿瘤中的转移细胞,以激发转移抑制治疗。
这项研究将由一名在分子病理学和系统生物学方面受过大量培训的学生进行
她希望继续她的癌症基因组学和生物信息学培训。实验动物人员将协助
在动物实验中,生物信息学主任将指导计算分析和统计测试,
导师/赞助商将监督实验和结果的解释。学生将密切合作
与赞助商和生物信息学合作者一起学习如何正确使用尖端基因组学,
生物信息学工具,以推进乳腺癌转移领域。此外,学生将获得
专业发展机会,如参加会议,指导本科生,
教授一门暑期课程,为她在癌症相关领域的博士后职位做准备。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tatyana Lev其他文献
Tatyana Lev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 4.24万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 4.24万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 4.24万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 4.24万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 4.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 4.24万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 4.24万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 4.24万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 4.24万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 4.24万 - 项目类别: